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Assuming no wastage, as in Method 3, may be unrealistic due to drug instability when stored, or an orphan drug’s use 
in a rare cancer posing logistical barriers to preparation for the population. However, the results of this analysis 
demonstrate the potential cost savings of dose banding, due to similar or lower drug costs and reduced administration 
time.
Limitations of the analysis include the lack of patient-level weight data for Stage IV melanoma. Weight in practice may 
differ from that of the general population due to illness or increased age. Additionally, of all melanoma diagnoses, 10% 
of males are diagnosed with Stage IV disease compared with 7% females.15 General population weight data could be 
adjusted to account for these differences.
Economic evaluations incorporating the costs of systemic anti-cancer therapies should include scenarios with dose 
banding where relevant. Further guidance on the methods for doing so may help standardise and proliferate such 
practices.
In 2016/2017, the National Health Service England (NHSE) spent approximately £1.7 billion on routinely commissioned 
chemotherapy.1 Drug costs were the largest proportion of this spend (80%) and are increasing at a high rate.1
Chemotherapy drugs, also known as systemic anti-cancer therapies, are commonly dosed variably, according to patient 
weight or body surface area. This can lead to wastage as large volumes of drug are left over in vials. It is often not 
possible to use left-over drug product for other patients due to practical, logistical or regulatory reasons.
To improve value and increase efficiency, recent NHSE guidance encourages hospitals to use dose banding, whereby 
individualised doses are rounded up or down to predetermined standard doses.1, 2 The exact, individualised dose is first 
calculated, which will fall into a range (or band) of doses corresponding to a single dose, permitting doses to be 
rounded down or up. Doses can also be made up in advance. Therefore, dose banding is expected to lead to 
efficiencies by reducing both drug wastage and administration time, while providing doses that do not affect efficacy or 
toxicity.3
The National Institute for Health and Care Excellence (NICE) has released a position statement supporting the 
approach,3 although how to apply dose banding in economic evaluations to inform NICE Health Technology 
Assessment (HTA) decisions remains unclear. As drug costs are invariably a key driver of results, it is important to 
acknowledge the potential impact of dose banding.
This study aimed to estimate annual drug and administration costs per patient, using the example of variably dosed 
Stage IV melanoma treatments for which dose-banding guidance is available. Annual per-patient drug and 
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Further information is available on request. Please visit BresMed at Stand 605. 
Distributions for total mg per dose for (1) non-banded dosing and (2) banded dosing assuming individual preparation are 
presented in Figure 1. 
For ipilimumab and pembrolizumab, Method 2 (dose banding assuming individual preparation) resulted in per-patient, annual 
drug cost savings of 6.4% (£4,581) and 9.1% (£3,143), respectively, versus Method 1 (non-banded dosing assuming 
individual preparation). For dacarbazine, this method led to a 0.3% increase in annual drug costs (+£0.88). Method 3 (exact 
dose and no wastage due to preparation for the population) led to savings of between 3.9% and 15.6% compared with 
Method 1. Estimated annual cost savings due to reduced administration time ranged from £283 to £453. Results are 
summarised in Tables 4 and 5.
Figure 1: Total milligrams per dose for all treatments based on a log normal fit to Health Survey for England data
Table 4: Estimated annual drug cost savings from adopting dose banding for Stage IV melanoma treatments
Annual drug cost per patient (£) Annual cost savings compared with no 



















Exact dose, no wastage, 
population preparation 
cost saving (£,%)
Dacarbazine £320 £321 £308 −£0.88, −0.3% £12, 3.9%
Ipilimumab £71,124 £66,544 £62,902 £4,581, 6.4% £8,222, 11.6%
Pembrolizumab £34,503 £31,360 £29,127 £3,143, 9.1% £5,377, 15.6%
Annual administration cost 
per patient: 
no banding
Annual administration cost per 
patient: banding
Annual cost savings of banding 
compared with no banding cost 
saving (£,%)
Dacarbazine £1,135 £852 £283, 24.9%
Ipilimumab £1,223 £918 £305, 24.9%
Pembrolizumab £1,819 £1,366 £453, 24.9%
Table 5: Estimated annual administration cost savings from adopting dose banding for Stage IV melanoma treatments
Drug costs
Dose banding guidance is available for three systemic anti-cancer therapies for Stage IV melanoma: dacarbazine, 
ipilimumab and pembrolizumab. Dacarbazine is available in 100mg and 200mg vial sizes and was assumed to be 
administered at a dose of 850mg/m2 based on NICE TA319.4 Dacarbazine 200mg vials are cheaper per mg than 100mg 
vials, so it was assumed that clinicians would choose one 200mg vial over two 100mg vials where possible. Ipilimumab was 
assumed to be administered at 3mg/kg, and pembrolizumab at 2mg/kg, as specified in their Summaries of Product 
Characteristics (SPCs).5, 6 As ipilimumab and pembrolizumab vials are divisible and linearly priced, the smallest vial size was 
used in the analysis for simplicity. Preparation strengths, pack sizes and costs were taken from the electronic Market 
Information Toot (eMIT) and the Monthly Index of Medical Specialities (MIMS).7, 8 List prices were used for all drugs. 
Table 1 summarises the drug costs used in the analysis.









Dacarbazine 100mg powder 
for solution for injection vials
10mg/ml 10 1000 £46.15 £0.046 £4.62 eMIT7
Dacarbazine 200mg powder 
for solution for injection vials
10mg/ml 10 2000 £86.65 £0.043 £8.67 eMIT7
Ipilimumab 5mg/ml 
concentrate for solution for 
infusion in vial, 10ml (50mg)
5mg/ml 1 50 £3,750.00 £75.00 £3,750.00 MIMS8
Pembrolizumab 50mg 
powder for concentrate for 
solution for infusion in vial
25mg/ml 1 50 £1,315.00 £26.30 £1,315.00 MIMS8
Key: eMIT, electronic Market Information Tool; MIMS, Monthly Index of Medical Specialities.
Notes: *List prices used for drug costs.
Table 1: Stage IV melanoma treatments, posology and costs
Administration costs
Administration regimens were taken from the SPCs,5, 6, 9 and costed using NHS reference costs 2015 to 2016.10 Dacarbazine 
and pembrolizumab were assumed to need simple parenteral regimens whereas ipilimumab was assumed to need a more 
complex regimen based on the extended infusion time required.11 Table 2 summarises the administration costs used in the 
analysis.





or infusion over 15–30 
minutes
On day 1 and then once 
every 3 weeks as 
intravenous infusion




Intravenous over a 90-
minute period
Every 3 weeks







Deliver simple parenteral 
chemotherapy
SB12Z £253.00
Key: HRG, Healthcare Resource Group.
Table 2: Stage IV melanoma treatments, administration costs
Due to a lack of literature on the topic, assumptions were made about the reduction in administration time due to dose 
banding. It was assumed that the complex regimen for ipilimumab would become a simple one leading to a cost saving of 
24.9% (calculated from Table 2), and that the simple regimens for dacarbazine and pembrolizumab would be associated 
with proportionate cost savings though reduced administration time.*
Treatment duration
Data on treatment duration were taken from NICE TA319, TA268 and TA366 for dacarbazine, ipilimumab and 
pembrolizumab.4, 12, 13 Average numbers of administrations per year were 4.49, 3.63 and 7.19, respectively.
Weight data
As proxies for weight and body surface area of patients with Stage IV melanoma, general population data from the Health 
Survey for England were used. Porter and colleagues fitted log normal distributions to these data (Table 3).14 Parameters 
were used to inform the average cost of treatment.
Costing methods
Three drug costing methods were explored and compared: (1) non-banded dosing assuming individual preparation, (2) 
banded dosing assuming individual preparation and (3) non-banded exact dosing, assuming no drug wastage due to 
preparation for the population. For the methods assuming individual preparation (i.e. Methods 1 and 2), the moments of the 
distributions of patient weight (ipilimumab and pembrolizumab) and body surface area (dacarbazine) shown in Table 3 were 
used to determine the proportion of patients requiring each vial size or falling into each dose band. For Method 3, mean 




Key: BSA, body surface area.
Table 3: Log normal distribution of weight and body surface area, fitted to Health Survey for England data
Notes: A and B: dacarbazine; C and D: ipilimumab; E and F: pembrolizumab.
BandingNo banding
*In the submitted abstract, this figure was estimated to be 29%. Since acceptance of the abstract, this value was found to be describing an incorrect cost 
saving related to the implementation of dose banding. Therefore, the analysis was updated to use 24.9% as described in the poster text. Consequently, 
some of the results included within the Results section are different to those in the submitted abstract. The authors apologise for any confusion caused.
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